OBJECTIVES: Inflammatory molecules play a role in the development of atherosclerosis, which is the primary origin of cardiovascular disorders. However, to the best of our knowledge, no study has attempted to investigate the relationship between these circulating molecules and the prediction of cardiovascular risk. The present study aimed to investigate the relationships of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, E-selectin and matrix metalloproteinase 9 serum concentrations with the extent of coronary lesions.

METHODS: Seventy-four individuals who were undergoing coronary angiography for the first time for diagnostic purposes were enrolled in this study. The extent of the coronary lesion was assessed using the Friesinger Index, and subjects were classified into four groups: no lesions, minor lesions, intermediate lesions and major lesions. Serum biochemical parameters and serum concentrations of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, E-selectin and matrix metalloproteinase 9 were analyzed.

RESULTS: The vascular cell adhesion molecule-1 concentration was higher than 876 ng/mL in individuals with intermediate and major lesions ($p < 0.001$ and $p = 0.020$, respectively). Moreover, logistic regression analysis showed that these patients had an increased risk of having an intermediate lesion ($p = 0.007$). Interestingly, all individuals with major lesions had vascular cell adhesion molecule-1 concentrations higher than 876 ng/mL. No association was found between the concentrations of the other proteins and the Friesinger Index.

CONCLUSIONS: Serum vascular cell adhesion molecule-1 may be associated with the extent of coronary lesions. Moreover, it may represent an alternative to improve the cardiovascular risk classification in patients without acute coronary syndrome.

KEYWORDS: VCAM-1; Cardiovascular Diseases; Atherosclerosis; Inflammatory Molecules.
VCAM-1 and the extent of coronary lesions

Santos JC et al.

E-selectin, can reflect the inflammatory process in the endothelium. Together, these molecules form an integrated and overlapping system for the transport of leukocytes into the vascular wall and play an active role in the development of atherosclerotic plaques (7). Moreover, matrix metalloproteinases (MMPs) play important roles in thrombogenesis by disrupting atherosclerotic plaques and participating in the degradation of the extracellular matrix (8,9).

However, few studies have shown an association between increased expression of these proteins in tissues and their soluble level in the plasma. Also, to the best of our knowledge, no studies have associated these molecules with the early atherosclerotic process and the coronary atherosclerotic burden in humans (2,10,11). Previous studies have investigated these molecules in patients with acute coronary syndrome and even post-infarction patients, but no study has evaluated these molecules prior to cardiovascular events.

Therefore, the aim of this study was to investigate a possible relationship between circulating VCAM-1, ICAM-1, E-selectin or MMP9 and the extent of coronary lesions in patients without acute coronary syndrome nor post-infarction patients. These results may contribute to the identification of potential biomarkers and the development of non-invasive methods for the diagnosis of atherosclerosis, thus reducing health costs and cardiovascular risk.

## MATERIALS AND METHODS

### Study population

Seventy-four male and female individuals aged between 30 to 74 years who were undergoing coronary angiography at the hemodynamics Department of University Hospital Onofre Lopes (HUOL) for diagnostic purposes were enrolled in the present study. Subjects with cardiomyopathy, including Chagas disease, heart valve disease, congenital diseases, and pericarditis, and subjects with an angioplasty or stent were excluded from this study. Additionally, patients with familial hypercholesterolemia or the presence of chronic kidney disease, liver failure, endocrine disorders (except for diabetes mellitus), inflammatory diseases, malignant diseases, blood disorders, autoimmune diseases were excluded. The study was conducted in accordance with the guidelines set by the Ethics in Research Committee of the Federal University of Rio Grande do Norte and complies with the Declaration of Helsinki (protocol CAAE 0001.0.051.294-11). All participants signed an informed consent form.

### Extent of coronary lesions

The extent of the coronary lesions was assessed using the Friesinger Index (12–14). Each of the three main coronary arteries (anterior descending, circumflex and right coronary) was scored separately from zero to five. The subjects were classified as follows: no lesion when the Friesinger Index was equal to 0; minor lesion when the Index varied from 1–5; intermediate lesion when the Index varied from 6–10; and major lesion when the Index varied from 11–15, as adapted from Chagas et al. (15).

### Blood samples and biochemical analysis

Peripheral venous blood samples were obtained from the patients. Fasting serum glucose, total cholesterol and fractions, urea, creatinine K, uric acid, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using colorimetric and colorimetric-enzymatic (Labtest, Minas Gerais, Brazil) methods on a semi-automatic biochemical analyzer (BIO-2000 IL, Bioplus, SP, Brazil). The LDL level was calculated according to the formula described by Friedewald et al. (16).

A multiplex immunoassay using polystyrene beads based on the Luminex technology was performed since the VCAM-1, ICAM-1, E-selectin and MMP9 molecules were found in small amounts in the blood. The Milliplex® MAP Human CVD Panel 1 Immunoassay Kit (Merck KGaA, Darmstadt, Germany) was used according to the manufacturer’s instructions. Briefly, the samples were mixed with antibody-linked polystyrene beads in 96-well filter-bottom plates and incubated at room temperature for 2h, followed by overnight incubation at 4°C. The plates were vacuum filtered, washed twice with wash buffer, and then incubated with a biotinylated detection antibody for 1h at room temperature. Streptavidin–phycoerythrin was added to the sample. After incubation for 30 min at room temperature and two additional vacuum washes, the samples were resuspended in reading buffer. Each sample was measured in duplicate. The plates were read using a Luminex® 100/200™ System (Luminex, Austin, TX, USA) with a lower bound of 100 beads per sample per cytokine.

### Statistical analysis

The statistical analyses were performed using the SPSS software v20.0 (SPSS Inc., Chicago, IL, USA). The data were categorized in two conditions: 1. Friesinger Index groups (no lesion, minor lesion, intermediate lesion and major lesion) and 2. Tertile concentrations of inflammatory molecules (1st, 2nd and 3rd). Categorical variables were shown as percentages and compared using the Chi-square test. Continuous variables were presented as the mean and standard deviation and compared using the Kruskal–Wallis test or ANOVA, followed by Tukey’s post hoc test according to the normality of the distribution assessed using the Kolmogorov–Smirnov test. Spearman’s correlation was used to calculate correlations between the inflammatory protein concentrations and the Friesinger Index. Logistic regression analyses were used to evaluate the relationships between the increases in serum inflammatory molecules and the Friesinger Index. The level of statistical significance was set as \( p < 0.05 \).

## RESULTS

The patients were classified into four groups according to the extent of the coronary lesions evaluated by the Friesinger Index as follows: no lesion (31.0%), minor lesion (29.8%), intermediate lesion (27.0%) and major lesion (12.2%). The demographic, anthropometric, clinical and biochemical data collected from these groups are shown in Table 1 and Table 2. Significant differences in the clinical and biochemical data were not found among the groups.

The categorization of the adhesion molecules and MMP9 into tertiles showed that patients with intermediate and major lesions had VCAM-1 concentrations >876 ng/mL (2nd and 3rd tertiles), whereas patients with no or minor lesions had VCAM-1 concentrations <876 ng/mL (1st tertile, \( p < 0.05 \), Figure 1).

Additionally, the patients with VCAM-1 concentrations >876 ng/mL had a 9.81-fold higher risk of having intermediate lesions (\( p < 0.01 \); OR: 9.81; 95% CI: 1.84 – 52.38, Table 3). In this study, all patients with major lesions had VCAM-1 concentrations >876 ng/mL. E-selectin, ICAM-1 and MMP9
were not associated with the Friesinger Index, although VCAM-1 was correlated with ICAM-1 and the extent of the coronary lesion ($p<0.01$, $r^2=0.40$; and $p=0.02$, $r^2=0.29$, respectively).

**DISCUSSION**

The primary origin of CAD is atherosclerosis, which is a chronic inflammatory process that induces the expression of adhesion molecules at the endothelial membrane. VCAM-1, ICAM-1 and E-selectin promote the connection of leukocytes and their migration into the intima, whereas MMP9, a metalloproteinase, plays a special role in the instability of atherosclerotic plaques. These molecules can also be found in the serum in a soluble form due to the proteolytic rupture of cellular membranes in which adhesion molecules are expressed. Therefore, their measurement can be evaluated in several clinical situations in which inflammation is a causal contributor, making these molecules easily accessible serum markers (2,17,18).

Interestingly, in the present study, it was observed that patients with intermediate and major lesions had high VCAM-1 concentrations (>876 ng/mL). In addition, the logistic regression analysis indicated that patients subjected to coronary angiography with VCAM-1 levels higher than 876 ng/mL had a 9.8-fold greater risk of having atherosclerotic lesions (intermediate lesions), whereas ICAM-1 values higher than 876 ng/mL had a 9.8-fold greater risk of having atherosclerotic plaques. These results suggested a possible VCAM-1 cut-off value that may aid in the determination of the extent of coronary lesions.

A previous study with 855 patients diagnosed with stable carotid atherosclerosis over a 6.2-year period observed that VCAM-1 values higher than 837 ng/mL increased the cardiovascular mortality risk by 2.5-fold and predicted future cardiovascular events, whereas ICAM-1 values higher than 335 ng/mL increased that risk by 3.4-fold; these results indicated that these molecules were strong and independent predictors of mortality in patients with stable carotid atherosclerosis (2). In contrast, another study that enrolled 15 patients with major lesions had a VCAM-1 concentration >876 ng/mL, thereby suggesting a possible VCAM-1 cut-off value that may aid in the determination of the extent of coronary lesions.
No significant difference was observed between serum levels of ICAM-1 and the extent of coronary lesions; however, an indirect positive correlation between these factors was revealed, as VCAM-1 correlated with the Friesinger Index and VCAM-1 correlated with ICAM-1 serum levels. This result could be due to the lower ICAM-1 concentrations found in the subjects enrolled in the present study (\(<250 \text{ ng/mL}\)).

Moreover, the considerable controversies were found in the literature about the predictive values of ICAM-1 and VCAM-1 may be explained by the characteristics of both molecules. ICAM-1 seems to be a natural marker of pro-inflammatory conditions, whereas VCAM-1 is rapidly induced by pro-atherosclerotic circumstances.

Regarding MMP9 and E-selectin, significant results were not found in the present study. MMP9 plays a critical role in the later stages of atherosclerotic lesions, particularly in the rupture of the atherosclerotic plaque (17,20). MMP9 concentrations were significantly increased in aortic samples from 89 patients who underwent a surgical procedure for abdominal aortic aneurysms (21). Also, soluble MMP9 was associated with vulnerable atherosclerotic plaques in 88 patients who experienced a major adverse cardiovascular event in a cohort study over a 3-year period (20). In the present study, only patients with no history of acute coronary syndrome who underwent coronary angiography for the first time were included, and we found that 60.8% of our patients had only minor or no atherosclerotic lesions. These aspects may account for the absence of high serum levels of MMP9 in our study population.

Regarding E-selectin, the absence of an association between E-selectin and the extent of coronary lesions in the present study could be explained by the involvement of this molecule in the early nonspecific stages of leukocyte adherence and rolling. This result was also observed by other authors, whom also did not associate soluble E-selectin with adverse clinical outcomes in 855 patients diagnosed with stable carotid atherosclerosis (2) or in a study evaluating 65 patients with acute coronary syndrome (22).

The present results are important, particularly regarding VCAM-1 serum levels, because no atherosclerotic lesions...
were detected in 31% of the patients, and the high frequency of patients without lesions who were subjected to an invasive procedure in both studies indicates a clear need to establish new tests to complement and aid CAD diagnosis. Similar data were recently reported in a study of 100 patients of both genders undergoing coronary angiography for diagnostic purposes, showing that 37% of those patients had no atherosclerotic lesions (12). Our hypothesis is also supported by other authors, whom have emphasized the absence of non-invasive methods, clinical symptoms or laboratory tests that are capable of detecting individuals who will develop CAD (1).

A major limitation of the present study was the small sample size, as our pilot study population consisted of patients without previous acute cardiac events who were referred for diagnostic coronary angiography for the first time. However, it is important to highlight that this was the first study to evaluate circulating inflammatory molecules and their relationships with the extent of coronary lesions in patients without acute coronary syndrome.

Some of the established major vascular risk factors are not observed in over 20% of patients who develop coronary events (23). Thus, using markers involved in the atherosclerotic process may lead to better, earlier and more accurate risk predictions for CVDs. In addition, non-invasive methods and laboratory tests play an important role in decreasing health costs and improving quality of life among patients.

In conclusion, circulating VCAM-1 might be associated with the extent of coronary lesions in patients with a risk of developing acute coronary syndrome. In addition, this result suggests that VCAM-1 may also be associated with the prediction of cardiovascular disease and the severity of atherosclerosis. Further investigation is required to validate this hypothesis and to determine whether monitoring VCAM-1 serum levels may be valuable for the assessment of cardiovascular risk.

**ACKNOWLEDGMENTS**

We would like to acknowledge all patients and our colleagues for their contributions to this study. This study was supported by grants from FAPERN (005/2011) and CNPQ (483031/2013-5).

**AUTHOR CONTRIBUTIONS**

Silbiger VN and Luchessi AD were responsible for the original concept of the study and study design. Santos JC, Oliveira KM, Araújo JN, Duarte VH, Silva AM and Santos IC were responsible for the recruitment of the patients, collection of the samples and the laboratory analysis. Bortolin RH, Santos JC, Cruz MS, Dantas JM, Paiva MS, Luchessi AD and Silbiger VN interpreted the results and performed the statistical analyses. Bortolin RH, Santos JC, Cruz MS, Araújo JN, Luchessi AD and Silbiger VN wrote the manuscript. Bortolin RH, Rezende AA, Hirata MH, Hirata RD, Luchessi AD and Silbiger VN were responsible for the critical revision of the manuscript.

**REFERENCES**

1. Andrade WS, Oliveira P, Laydner H, Ferreira EJ, Barreto-Filho JI. Severity of erectile dysfunction is highly correlated with the syntax score in patients undergoing coronary angiography. Int Braz J Urol. 2016;42(1):123-31, http://dx.doi.org/10.1590/S1677-5538.IBJU.2015.0002

2. Hoke M, Winter M, Wagner O, Exner M, Schilling M, Arnold Z, et al. The impact of selectins on mortality in stable carotid atherosclerosis. Thromb Haemost. 2015;114(3):632-8, http://dx.doi.org/10.1160/TH14-12-1014

3. Borrow KM, Nelson JR, Mason BP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242(1):357-66, http://dx.doi.org/10.1016/j.atherosclerosis.2015.07.035

4. Pereira-Duque MA, Romero-Barral JL, Gaxiola-Macias MB, Arias-Sánchez EA. Coronary Atherosclerosis and Interventional Cardiology. Arch Med Res. 2015;46(5):372-8, http://dx.doi.org/10.1016/j.arcmed.2015.06.005

5. Fark E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1999;99(2):557-71, https://dx.doi.org/10.1161/01.CIR.99.2.557

6. Goel S, Miller A, Agarwal C, Zakin E, Acholonu M, Gidwani U, et al. Imaging Modalities to Identity Inflammation in an Atherosclerotic Plaque. Radiol Res Pract. 2015;2015:410967, http://dx.doi.org/10.1155/2015/410967

7. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(11):2292-301, http://dx.doi.org/10.1161/ATVBAHA.107.149179

8. Murillo CA, Woodside KJ, Guo Q, Zhang S, O’Connor KL, Hunter GC. Integrin and matrix metalloproteinase expression in human carotid plaque. J Surg Res. 2009;155(1):137-64, http://dx.doi.org/10.1016/j.jsres.2008.08.005

9. Rao VH, Kansal V, Stoupa S, Agrawal DK. MMP-1 and MMP-9 regulate epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells. Physiol Rep. 2014;2(2):e00224, http://dx.doi.org/10.1101/phy.2.224

10. Wang KF, Huang PH, Chiang CH, Hsu CY, Lee HB, Chen JW, et al. usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction. Coron Artery Dis. 2013;24(4):23-8, http://dx.doi.org/10.1097/MCA.0b013e32836aa5d4a

11. Mu W, Chen M, Gong Z, Zheng F, Xing Q. Expression of vascular cell adhesion molecule-1 in the aortic tissues of atherosclerotic patients and the associated clinical implications. Exp Ther Med. 2015;10(3):423-8, http://dx.doi.org/10.3892/etm.2015.3254

12. Bampi AB, Rochitte CE, Favaretto D, Lemos PA, da Luz PL. Comparison of non-invasive methods for the detection of coronary atherosclerosis. Clinics. 2009;64(7):675-82, http://dx.doi.org/10.1590/S1807-932220090 700012

13. Duarte MK, de Araújo JN, Duarte VH, de Oliveira KM, de Oliveira JM, Carioca AA, et al. The relationship of the oleic acid level and ECHOD3 mRNA expression with the extent of coronary lesion. Lipids Health Dis. 2016;15(4):144, http://dx.doi.org/10.1186/s12946-016-0312-6

14. Ringqvist I, Fisher LD, Mock M, Davis KB, Wedel H, Chaitman BR, et al. Prognostic value of angiographic indices of coronary artery disease from the coronary artery surgery study (cASS). J Clin Invest. 1983;70(6):1854-66, http://dx.doi.org/10.1172/JCI110941

15. Chagas P, Caramori P, Galdino TP, Barcelos Cda S, Gomes I, Schwaneke CH. Egg consumption and coronary atherosclerotic burden. Atherosclerosis. 2013;229(2):381-4, http://dx.doi.org/10.1016/j.atherosclerosis.2013.05.008

16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502

17. Newby AC. Metalloproteinases promote plaque rupture and myocardial infarction: A persuasive concept waiting for clinical translation. Matrix Biol. 2014;44-46:157-66, http://dx.doi.org/10.1016/j.matbio.2015.01.015

18. Soto ME, Reyes-Villatoro MA, Márquez R, Cardoso G, Posadas-Sánchez R, Juárez-Orozco LE. Evaluation and analysis of plasma soluble adhesion molecules in patients with coronary ectasia and atherosclerotic coronary artery disease. Arch Med Res. 2014;45(6):478-83, http://dx.doi.org/10.1016/j.arcmed.2014.07.002

19. Bayata S, Arikan E, Yesil M, Postaci N, Tas A, Koseoglu M. An important role for VCAM-1, but not for ICAM-1 in restenosis following coronary stent implantation. Anadolu Kardiyol Derg. 2010;10(5):405-9, http://dx.doi.org/10.5152/akd.2010.137

20. Cheng JM, Akkerhuis KM, Meibach O, Oemrawsingh RM, Garcia-Garcia HM, van Geuns RJ, et al. circulating osteocalcin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography. Arterioscler Thromb Vasc Biol. 2014;34(5):1078-84, http://dx.doi.org/10.1161/ATVBAHA.114.303486

21. Dilmene JF, Bellmunt S, Camacho M, Sola-Valls D, Romero JM, Escudero JR, et al. Influence of cardiovascular risk factors on levels of matrix metalloproteinases 2 and 9 in human abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2014;48(4):374-81, http://dx.doi.org/10.1016/j.ejvs.2014.05.023

22. Yüksel A, Bilgir F, Bilgir O, Calan M, Bozkaya G. Increased circulating monocyte migration inhibitory factor levels are associated with coronary artery disease. Clinics. 2015;70(3):169-72, http://dx.doi.org/10.6061/clinics/2015.0303

23. Gomes MA, Bispo IC, Neto NC. Marcadores Laboratoriais Não Tradicionais para Aterosclerose: revisão de literatura. Rev SocBR. 2009;22(5):318-25.